ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
RPG Life Sciences announced the amalgamation of its wholly-owned subsidiary, Actis Generics, into its other subsidiary, RPG Active Pharma Limited. No share exchange is involved.
RPG Life Sciences completed the slump sale of its API and intermediates business to Raghava Life Sciences Private Limited, effective September 16, 2026.
RPG Life Sciences' subsidiary, RPG Active Pharma, allotted shares to India Life Sciences Fund and Vistaject Fund for ₹243.33 crores. Post-allotment, RPG Active Pharma remains a subsidiary.
RPG Life Sciences' subsidiary will acquire the API and intermediates business of Raghava Life Sciences for Rs. 135 Crore via a slump sale.
RPG Life Sciences Limited completed the slump sale transfer of its Active Pharmaceuticals Ingredients (API) business to its wholly-owned subsidiary, RPG Active Pharma Limited.
RPG Life Sciences will invest up to ₹65.69 Crore in its wholly-owned subsidiary, RPG Active Pharma Limited, through a subscription to a rights issue of equity shares.
RPG Life Sciences is selling its API business to its wholly-owned subsidiary, RPG Active Pharma Limited, for a consideration of ₹33.55 Crore.
RPG Life Sciences' subsidiary, RPG Active Pharma, signed an investment agreement with ILSF and Vistaject. The deal involves an initial Rs. 243.33 crore capital infusion.
RPG Life Sciences will transfer its API business to subsidiary RPG Active Pharma and acquire Actis Generics. InvAscent will invest up to ₹700 Crore in the entity.
RPG Life Sciences will sell its API business for Rs. 33.55 Crore to its subsidiary and raise Rs. 243.33 Crore from investors in that subsidiary.